Key result
Recent trials support the use of LMWH, pentasaccharide, and direct thrombin inhibitors for the prevention of venous thromboembolism in patients undergoing major orthopaedic surgery.
Why the study?
What is the optimal agent, timing, and duration of antithrombotic prophylaxis for preventing venous thromboembolism in patients undergoing total hip replacement?
Population
Patients undergoing total hip replacement
Comparison
Antithrombotic therapy with varying timing and… vs Current practice or alternative antithrombotic…
Design
Review
Authors
Loading...
May inform VTE prophylaxis choices in major orthopaedic surgery; leaves open optimal agent, timing, and duration for total hip replacement.
What is the optimal agent, timing, and duration of antithrombotic prophylaxis for preventing venous thromboembolism in patients undergoing total hip replacement?
This review highlights the evolving evidence for newer antithrombotic agents and optimized timing and duration of prophylaxis to prevent VTE in total hip replacement.
André Kher (2001) conducted a review in Venous thromboembolism in patients undergoing total hip replacement. Antithrombotic therapy (LMWH, oral anticoagulants, pentasaccharide, direct thrombin inhibitors) was evaluated on Venous thromboembolism / deep vein thrombosis. Recent trials support the use of LMWH, pentasaccharide, and direct thrombin inhibitors for the prevention of venous thromboembolism in patients undergoing major orthopaedic surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: